By Nick Paul Taylor
AstraZeneca has put clinical development of its COVID-19 vaccine on hold in response to an adverse event, sparking a reassessment of the race to bring a coronavirus prophylactic to market.
read more
By Tina Reed
Surgeon general on COVID-19 vaccine development: "There will be no shortcuts."
read more
By Kyle Blankenship
In the hunt for a COVID-19 vaccine, no front-runner is moving as quickly as Pfizer and BioNTech's mRNA-based shot, which is scoping an October regulatory review. Despite some technical concerns about their proposed rollout plans, the partners are moving ahead with their largest supply deal yet.
read more
By Tina Reed
As president of Walmart Health, Sean Slovenski was sitting in one of the most influential positions when it came to U.S. healthcare. So, why did he just leave the gig to work at a far smaller firm that specializes in diagnostic testing? The answer is complicated, Slovenski said.
read more
By Conor Hale
Shortly after unveiling a portable, digital testing system for COVID-19 antibodies late last month, Qiagen has now announced plans to leverage the same platform for a rapid antigen test to identify active coronavirus infections.
read more
By Kyle Blankenship
New Jersey contract manufacturer Catalent has been right in the mix in the COVID-19 response effort, signing pacts to help produce frontrunners in the vaccine hunt. Now, the company is fleshing out a Maryland facility to aid in that effort—and position Catalent's cell and gene therapy offerings well into the future.
read more
By Ben Adams
OncoImmune has raised $56 million in a series B as it looks to push on with late-stage tests for its experimental drug CD24Fc in both leukemia patients and its recent pivot to COVID-19.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
AstraZeneca's clinical hold may slow the pace of other vaccine trials, analysts figure. Pfizer and BioNTech's shot hopeful yielded strong immune data in animals. Sinovac's vaccine spurred a safe immune response in older adults. Catalent is expanding the Maryland site where it will produce AZ shots. And Qiagen plans to launch a rapid antigen test.
read more
By Arlene Weintraub
Pfizer and its partner BioNTech said Wednesday that their most advanced COVID-19 vaccine candidate produced neutralizing antibodies against the virus in macaques, as well as T cell responses that are believed to be an indicator of a strong immune attack. The data formed the basis of the current phase 2/3 trial in people.
read more
By Kyle Blankenship
AstraZeneca was humming right along with its partnered COVID-19 vaccine with the University of Oxford before a sudden trial hold threw its plans into disarray. So what does that uncertainty mean for AstraZeneca's expectant manufacturing partners on the shot? For at least one, it could be no issue at all.
read more
